Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Cash from Investing Activities (2016 - 2024)

Moleculin Biotech (MBRX) has 9 years of Cash from Investing Activities data on record, last reported at -$13000.0 in Q2 2024.

  • For Q2 2024, Cash from Investing Activities rose 13.33% year-over-year to -$13000.0; the TTM value through Mar 2025 reached -$13000.0, up 89.52%, while the annual FY2024 figure was -$13000.0, 89.52% up from the prior year.
  • Cash from Investing Activities reached -$13000.0 in Q2 2024 per MBRX's latest filing, up from -$81000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$2000.0 in Q1 2020 and bottomed at -$340000.0 in Q3 2020.
  • Average Cash from Investing Activities over 5 years is -$54272.7, with a median of -$18000.0 recorded in 2020.
  • The widest YoY moves for Cash from Investing Activities: up 86.67% in 2020, down 4150.0% in 2020.
  • A 5-year view of Cash from Investing Activities shows it stood at -$14000.0 in 2020, then crashed by 35.71% to -$19000.0 in 2021, then tumbled by 221.05% to -$61000.0 in 2022, then plummeted by 32.79% to -$81000.0 in 2023, then soared by 83.95% to -$13000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$13000.0 in Q2 2024, -$81000.0 in Q4 2023, and -$28000.0 in Q3 2023.